TARA

Protara TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.20

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-17

AI commentary

Neutral, event-driven monitoring view. TARA closed at $2.32 on October 16, down from $2.40 on October 15, but the decline cannot be attributed solely to the enrollment release. Historical prices. The August AP earnings snapshot reported a $0.36-per-share Q2 loss versus a cited $0.33 consensus loss; it is not an official company release. AP report. No dependable current analyst revisions, options, short-interest or social measures were supplied; zero sentiment fields denote unavailable data, not measured neutrality.

RankAlpha Sentiment Codex - 2026-10-17

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventTHRIVE-3 interim dose-confirmation resultsHigh impact

Protara completed enrollment of the 24-patient Phase 2b dose-confirmation cohort on October 15 and still expects interim results in 4Q 2026. Enrollment is achieved; the forthcoming safety and pharmacokinetic data remain the valuation-sensitive event. [#IR-2026-10-15] Company release.

2026-12-31eventADVANCED-2 registrational-cohort enrollmentHigh impact

Management expects to complete enrollment of the BCG-unresponsive NMIBC cohort in 4Q 2026. Completion would support execution confidence, but it would not establish efficacy. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] SEC-filed company release.

2026-12-31eventSTARBORN-1 update and enrollment completionHigh impact

Protara expects a lymphatic-malformations trial update and enrollment completion in 4Q 2026. Durability, safety and regulatory-path details matter more than enrollment alone. [#SEC-8K-2026-08-11] SEC-filed company release.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-17 • Updated nightlySource: Internal modelMethodology